<DOC>
	<DOC>NCT00182013</DOC>
	<brief_summary>The objective of this study is to compare the safety and effectiveness of Risperidone, Olanzapine, and Quetiapine in the treatment of mania in children and adolescents with Bipolar disorder over 8 weeks and then over an extension phase. This is an exploratory, open-label study, which seeks to determine if there is evidence for efficacy. The results of this study will be used to generate hypotheses for a larger study.</brief_summary>
	<brief_title>Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Males and females age 6 to 18 years of age Patient must have a diagnosis of bipolar I or bipolar II disorder and currently displaying an acute manic, hypomanic, or mixed episode (with or without psychotic features) according to the DSMIV based on clinical assessment and confirmed by structured diagnostic interview (Kidd Schedule of Affective Disorders). Patients must have an initial score on the YMRS total score of at least 15. Patient must be able to participate in mandatory blood draws. Patient must be able to swallow pills. Patients with chronic medical illness, DSMIV substance dependence within the past 6 months, pregnant or nursing females, and those at serious risk of suicide will be excluded from the study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>